{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:35:33Z","timestamp":1769751333930,"version":"3.49.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12894-018-0318-7","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T12:04:38Z","timestamp":1520424278000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Antihypertensive drugs use and the risk of prostate cancer: a meta-analysis of 21 observational studies"],"prefix":"10.1186","volume":"18","author":[{"given":"Liang","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-ming","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei-tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"318_CR1","first-page":"S3","volume":"6","author":"PS Vokonas","year":"1988","unstructured":"Vokonas PS, Kannel WB, Cupples LA. Epidemiology and risk of hypertension in the elderly: the Framingham study. Journal Hypertens Suppl. 1988;6:S3\u20139.","journal-title":"Journal Hypertens Suppl"},{"key":"318_CR2","doi-asserted-by":"publisher","first-page":"e002284","DOI":"10.1161\/JAHA.115.002284","volume":"5","author":"N Redmond","year":"2016","unstructured":"Redmond N, Booth JN 3rd, Tanner RM, Diaz KM, Abdalla M, Sims M, et al. Prevalence of masked hypertension and its association with subclinical cardiovascular disease in African Americans: results from the Jackson heart study. J Am Heart Assoc. 2016;5:e002284.","journal-title":"J Am Heart Assoc"},{"key":"318_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/HJH.0000000000000447","volume":"33","author":"C Thomopoulos","year":"2015","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses. J Hypertens. 2015;33:195\u2013211.","journal-title":"J Hypertens"},{"key":"318_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957\u201367.","journal-title":"Lancet"},{"key":"318_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/ijc.2910180603","volume":"18","author":"A Aromaa","year":"1976","unstructured":"Aromaa A, Hakama M, Hakulinen T, Saxen E, Teppo L, Ida lan-Heikkila J. Breast cancer and use of rauwolfia and other antihypertensive agents in hypertensive patients: a nationwide case-control study in Finland. Int J Cancer. 1976;18:727\u201338.","journal-title":"Int J Cancer"},{"key":"318_CR6","first-page":"817","volume":"76","author":"JL Stanford","year":"1986","unstructured":"Stanford JL, Martin EJ, Brinton LA, Hoover RN. Rauwolfia use and breast cancer: a case-control study. J Natl Cancer Inst. 1986;76:817\u201322.","journal-title":"J Natl Cancer Inst"},{"key":"318_CR7","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S0140-6736(75)91826-7","volume":"1","author":"AR Dyer","year":"1975","unstructured":"Dyer AR, Stamler J, Berkson DM, Lindberg HA, Stevens E. High blood-pressure: a risk factor for cancer mortality? Lancet. 1975;1:1051\u20136.","journal-title":"Lancet"},{"key":"318_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","volume":"352","author":"AF Lever","year":"1998","unstructured":"Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352:179\u201384.","journal-title":"Lancet"},{"key":"318_CR9","doi-asserted-by":"publisher","first-page":"E1073","DOI":"10.1503\/cmaj.101497","volume":"183","author":"C Yoon","year":"2011","unstructured":"Yoon C, Yang HS, Jeon I, Chang Y, Park SM. Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies. Can Med Assoc J. 2011;183:E1073\u2013E84.","journal-title":"Can Med Assoc J"},{"key":"318_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/1097-0142(20000701)89:1<165::AID-CNCR21>3.0.CO;2-G","volume":"89","author":"HT Sorensen","year":"2000","unstructured":"Sorensen HT, Olsen JH, Mellemkjaer L, Marie A, Steffensen FH, McLaughlin JK, et al. Cancer risk and mortality in users of calcium channel blockers. A cohort study. Cancer. 2000;89:165\u201370.","journal-title":"Cancer"},{"key":"318_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S0140-6736(97)80084-0","volume":"349","author":"H Jick","year":"1997","unstructured":"Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium-channel blockers and risk of cancer. Lancet. 1997;349:525\u20138.","journal-title":"Lancet"},{"key":"318_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1159\/000474185","volume":"30","author":"GA Dijkman","year":"1996","unstructured":"Dijkman GA, Debruyne FM. Epidemiology of prostate cancer. Eur Urol. 1996;30:281\u201395.","journal-title":"Eur Urol"},{"key":"318_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s002800000262","volume":"48","author":"CR Jan","year":"2001","unstructured":"Jan CR, Lee KC, Chou KJ, Cheng JS, Wang JL, Lo YK, et al. Fendiline, an anti-anginal drug, increases intracellular Ca2+ in PC3 human prostate cancer cells. Cancer Chemother Pharmacol. 2001;48:37\u201341.","journal-title":"Cancer Chemother Pharmacol"},{"key":"318_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1158\/1055-9965.EPI-03-0093","volume":"13","author":"JD Debes","year":"2004","unstructured":"Debes JD, Roberts RO, Jacobson DJ, Girman CJ, Lieber MM, Tindall DJ, et al. Inverse association between prostate cancer and the use of calcium channel blockers. Cancer Epidem Biomar. 2004;13:255\u20139.","journal-title":"Cancer Epidem Biomar"},{"key":"318_CR15","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s10552-011-9819-3","volume":"22","author":"KJ Kemppainen","year":"2011","unstructured":"Kemppainen KJ, Tammela TL, Auvinen A, Murtola TJ. The associationbetween anti-hypertensive drug use and incidence of prostate cancer in Finland: a population-based case\u2013control study. Cancer Causes Control. 2011;22:1445\u201352.","journal-title":"Cancer Causes Control"},{"key":"318_CR16","doi-asserted-by":"publisher","first-page":"e50893","DOI":"10.1371\/journal.pone.0050893","volume":"7","author":"L Azoulay","year":"2012","unstructured":"Azoulay L, Assimes TL, Yin H, Bartels DB, Schiffrin EL, Suissa S. Long-term use of angiotensin receptor blockers and the risk of cancer. PLoS One. 2012;7:e50893.","journal-title":"PLoS One"},{"key":"318_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1365-2125.2012.04170.x","volume":"74","author":"J Hallas","year":"2012","unstructured":"Hallas J, Christensen R, Andersen M, Friis S, Bjerrum L. Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study. Br J Clin Pharmacol. 2012;74:180\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"318_CR18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.amjcard.2011.03.038","volume":"108","author":"I Sipahi","year":"2011","unstructured":"Sipahi I, Chou J, Mishra P, Debanne SM, Simon DI, Fang JC. Meta-analysis of randomized controlled trials on effect of Angiotensin-converting enzyme inhibitors on cancer risk. Am J Cardiol. 2011;108:294\u2013301.","journal-title":"Am J Cardiol"},{"key":"318_CR19","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1023\/B:CACO.0000036152.58271.5e","volume":"15","author":"L Perron","year":"2004","unstructured":"Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control. 2004;15:535\u201341.","journal-title":"Cancer Causes Control"},{"key":"318_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2015.05.042","volume":"193","author":"PY Pai","year":"2015","unstructured":"Pai PY, Hsieh VC, Wang CB, Wu HC, Liang WM, Chang YJ, et al. Long term antihypertensive drug use and prostate cancer risk: a 9-year population-based cohort analysis. Int J Cardiol. 2015;193:1\u20137.","journal-title":"Int J Cardiol"},{"key":"318_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/oxfordjournals.epirev.a036298","volume":"9","author":"S Greenland","year":"1987","unstructured":"Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1\u201330.","journal-title":"Epidemiol Rev"},{"key":"318_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/humupd\/dms051","volume":"19","author":"C Siristatidis","year":"2013","unstructured":"Siristatidis C, Sergentanis TN, Kanavidis P, Trivella M, Sotiraki M, Mavromatis I, et al. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer--a systematic review and meta-analysis. Hum Reprod Update. 2013;19:105\u201323.","journal-title":"Hum Reprod Update"},{"key":"318_CR23","volume-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated march 2011]. The Cochrane collaboration","author":"JPTGS Higgins","year":"2011","unstructured":"Higgins JPT GS. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated march 2011]. The Cochrane collaboration. 2011; \n                    www.cochrane-handbook.org\n                    \n                  ."},{"key":"318_CR24","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/jcph.98","volume":"53","author":"GA Rao","year":"2013","unstructured":"Rao GA, Mann JR, Bottai M, Uemura H, Burch JB, Bennett CL, et al. Angiotensin receptor blockers and risk of prostate cancer among United States veterans. J Clin Pharmacol. 2013;53:773\u20138.","journal-title":"J Clin Pharmacol"},{"key":"318_CR25","doi-asserted-by":"publisher","first-page":"e2697","DOI":"10.1136\/bmj.e2697","volume":"344","author":"K Bhaskaran","year":"2012","unstructured":"Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK general practice research database. BMJ. 2012;344:e2697.","journal-title":"BMJ"},{"key":"318_CR26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10552-008-9280-0","volume":"20","author":"C Rodriguez","year":"2009","unstructured":"Rodriguez C, Jacobs EJ, Deka A, Patel AV, Bain EB, Thun MJ, et al. Use of blood-pressure-lowering medication and risk of prostate cancer in the cancer prevention study II nutrition cohort. Cancer Causes Control. 2009;20:671\u20139.","journal-title":"Cancer Causes Control"},{"key":"318_CR27","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/cncr.23215","volume":"112","author":"R van der Knaap","year":"2008","unstructured":"van der Knaap R, Siemes C, Coebergh JW, van Duijn CM, Hofman A, Stricker BH. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion\/deletion polymorphism, and cancer: the Rotterdam study. Cancer. 2008;112:748\u201357.","journal-title":"Cancer"},{"key":"318_CR28","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1016\/j.juro.2007.06.043","volume":"178","author":"AM Harris","year":"2007","unstructured":"Harris AM, Warner BW, Wilson JM, Becker A, Rowland RG, Conner W, et al. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol. 2007;178:2176\u201380.","journal-title":"J Urol"},{"key":"318_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1158\/1055-9965.EPI-03-0093","volume":"13","author":"JD Debes","year":"2004","unstructured":"Debes JD, Roberts RO, Jacobson DJ, Girman CJ, Lieber MM, Tindall DJ, et al. Inverse association between prostate cancer and the use of calcium channel blockers. Cancer Epidemiol, Biomarkers Prev. 2004;13:255\u20139.","journal-title":"Cancer Epidemiol, Biomarkers Prev"},{"key":"318_CR30","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1002\/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L","volume":"92","author":"S Friis","year":"2001","unstructured":"Friis S, Sorensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer. 2001;92:2462\u201370.","journal-title":"Cancer"},{"key":"318_CR31","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S1047-2797(01)00246-0","volume":"11","author":"AL Fitzpatrick","year":"2001","unstructured":"Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol. 2001;11:534\u201342.","journal-title":"Ann Epidemiol"},{"key":"318_CR32","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1161\/01.HYP.29.5.1091","volume":"29","author":"JH Olsen","year":"1997","unstructured":"Olsen JH, Sorensen HT, Friis S, McLaughlin JK, Steffensen FH, Nielsen GL, et al. Cancer risk in users of calcium channel blockers. Hypertension. 1997;29:1091\u20134.","journal-title":"Hypertension"},{"key":"318_CR33","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0140-6736(96)04277-8","volume":"348","author":"M Pahor","year":"1996","unstructured":"Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet. 1996;348:493\u20137.","journal-title":"Lancet"},{"key":"318_CR34","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/pds.1656","volume":"17","author":"TL Assimes","year":"2008","unstructured":"Assimes TL, Elstein E, Langleben A, Suissa S. Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiol Drug Saf. 2008;17:1039\u201349.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"318_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/pros.10294","volume":"58","author":"G Ronquist","year":"2004","unstructured":"Ronquist G, Garcia Rodriguez LA, Ruigomez A, Johansson S, Wallander MA, Frithz G, et al. Association between Captopril, other antihypertensive drugs and risk of prostate cancer. Prostate. 2004;58:50\u20136.","journal-title":"Prostate"},{"key":"318_CR36","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/S0895-7061(98)00176-9","volume":"11","author":"RM Vezina","year":"1998","unstructured":"Vezina RM, Lesko SM, Rosenberg L, Shapiro S. Calcium channel blocker use and the risk of prostate cancer. Am J Hypertens. 1998;11:1420\u20135.","journal-title":"Am J Hypertens"},{"key":"318_CR37","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/jama.279.13.1000","volume":"279","author":"L Rosenberg","year":"1998","unstructured":"Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD, Zauber AG, et al. Calcium channel blockers and the risk of cancer. JAMA. 1998;279:1000\u20134.","journal-title":"JAMA"},{"key":"318_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1158\/1055-9965.EPI-03-0093","volume":"13","author":"JD Debes","year":"2004","unstructured":"Debes JD, Roberts RO, Jacobson DJ, Girman CJ, Lieber MM, Tindall DJ, et al. Inverse association between prostate cancer and the use of Calcium Channel blockers. Cancer Epidemio Biomark Prev. 2004;13:255\u20139.","journal-title":"Cancer Epidemio Biomark Prev"},{"key":"318_CR39","doi-asserted-by":"crossref","unstructured":"Azoulay L, Assimes TL, Yin H, Bartels DB, Schiffrin EL, Suissa S. Long-term use of Angiotensin receptor blockers and the risk of cancer. PLoS One 2012;7:e50893.","DOI":"10.1371\/journal.pone.0050893"},{"key":"318_CR40","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1161\/HYPERTENSIONAHA.114.04262","volume":"64","author":"K Kario","year":"2014","unstructured":"Kario K, Saito I, Kushiro T, Teramukai S, Ishikawa Y, Mori Y, et al. Home blood pressure and cardiovascular outcomes in patients during antihypertensive therapy: primary results of HONEST, a large-scale prospective, real-world observational study. Hypertension. 2014;64:989\u201396.","journal-title":"Hypertension"},{"key":"318_CR41","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/2047487313510678","volume":"21","author":"HJ Heerspink","year":"2014","unstructured":"Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, et al. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. Eur J Prev Cardiol. 2014;21:299\u2013309.","journal-title":"Eur J Prev Cardiol"},{"key":"318_CR42","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.cjca.2013.08.012","volume":"30","author":"TR Richards","year":"2014","unstructured":"Richards TR, Tobe SW. Combining other antihypertensive drugs with beta-blockers in hypertension: a focus on safety and tolerability. Can J Cardiol. 2014;30:S42\u20136.","journal-title":"Can J Cardiol"},{"key":"318_CR43","doi-asserted-by":"publisher","first-page":"792","DOI":"10.2174\/157016110793563906","volume":"8","author":"A Karagiannis","year":"2010","unstructured":"Karagiannis A, Tziomalos K, Anagnostis P, Gossios TD, Florentin M, Athyros VG, et al. The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis. Curr Vasc Pharmacol. 2010;8:792\u2013803.","journal-title":"Curr Vasc Pharmacol"},{"key":"318_CR44","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1161\/01.HYP.8.11.1044","volume":"8","author":"S Landahl","year":"1986","unstructured":"Landahl S, Bengtsson C, Sigurdsson JA, Svanborg A, Svardsudd K. Age-related changes in blood pressure. Hypertension. 1986;8:1044\u20139.","journal-title":"Hypertension"},{"key":"318_CR45","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.urolonc.2013.08.001","volume":"32","author":"KR Loughlin","year":"2014","unstructured":"Loughlin KR. Calcium channel blockers and prostate cancer. Urol Oncol. 2014;32:537\u20138.","journal-title":"Urol Oncol"},{"key":"318_CR46","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1080\/02841860310022346","volume":"43","author":"H Lindberg","year":"2004","unstructured":"Lindberg H, Nielsen D, Jensen BV, Eriksen J, Skovsgaard T. Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncol. 2004;43:142\u201352.","journal-title":"Acta Oncol"},{"key":"318_CR47","first-page":"1139","volume":"2","author":"H Uemura","year":"2003","unstructured":"Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther. 2003;2:1139\u201347.","journal-title":"Mol Cancer Ther"},{"key":"318_CR48","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.tem.2005.07.009","volume":"16","author":"F Deshayes","year":"2005","unstructured":"Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrin Met. 2005;16:293\u20139.","journal-title":"Trends Endocrin Met"},{"key":"318_CR49","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2147\/OTT.S78836","volume":"8","author":"H Lu","year":"2015","unstructured":"Lu H, Liu X, Guo F, Tan S, Wang G, Liu H, et al. Impact of beta-blockers on prostate cancer mortality: a meta-analysis of 16,825 patients. OncoTargets Ther. 2015;8:985\u201390.","journal-title":"OncoTargets Ther"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-018-0318-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T00:24:32Z","timestamp":1551918272000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-018-0318-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1186\/s12894-018-0318-7","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,7]]},"assertion":[{"value":"23 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no conflict of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"17"}}